ApoRx Biopharmaceuticals

About

Q&A

What is ApoRx Biopharmaceuticals' primary focus?

ApoRx Biopharmaceuticals is a drug-discovery company focused on the discovery, design, characterization, and development of small proteolysis-targeting molecules against disease-causing proteins in cancer and other indications.

What is the core technology of ApoRx Biopharmaceuticals?

The core of ApoRx Biopharmaceuticals' technology is the Aperion library, a proprietary focus library of RING E3 ligase binders designed to harness the intracellular ubiquitin-proteasome machinery for targeted protein degradation.

When was ApoRx Biopharmaceuticals founded?

ApoRx Biopharmaceuticals was founded in January 2021.

How many employees does ApoRx Biopharmaceuticals have?

ApoRx Biopharmaceuticals has 4 employees, falling within the 1-10 employee bucket.

What is ApoRx Biopharmaceuticals' current funding stage?

ApoRx Biopharmaceuticals is currently in the Pre-Funding stage.

Who are the founders of ApoRx Biopharmaceuticals?

The founders of ApoRx Biopharmaceuticals include Avishai Levy (Co-founder & CEO), Omri Erez (Founder), Philippe Nakache (Co-founder), and Orna Harel (Co-founder).

What sector does ApoRx Biopharmaceuticals primarily operate in?

ApoRx Biopharmaceuticals' primary sector is Health Tech & Life Sciences.

What is the relationship between ApoRx Biopharmaceuticals and Agbiopro Protein Degradation Hub?

ApoRx Biopharmaceuticals is a subsidiary of Agbiopro Protein Degradation Hub, which is a management and consulting firm.

Team · 4

Avishai Levy

Founder · Co-founder & CEO

LinkedIn ↗

Omri Erez

Founder · Founder

LinkedIn ↗

Philippe Nakache

Founder · Co-founder

LinkedIn ↗

Orna Harel

Founder · Co-founder

LinkedIn ↗

Sectors & technology

Highlights

Tags